Which factor does not change PT or PTT but can lead to bleeding in rare patients?

Which factor does not change PT or PTT but can lead to bleeding in rare patients?

• A. Factor XIII.
• B. Factor VII.
• C. Factor XII.
• D. Factor II.

Answer: (A)

PT and aPTT measure the time it takes for initial clot formation, reflecting the enzymatic steps up to fibrin formation. Factor XIII is the final stabilizing step: it crosslinks and solidifies the fibrin clot after thrombin has formed fibrin. Because these tests assess how quickly a clot forms, not how well the formed clot is stabilized, a deficiency in Factor XIII does not lengthen PT or aPTT. Yet without crosslinking, the clot is unstable and can lead to clinically significant bleeding, even though routine screening tests are normal. This is why Factor XIII deficiency fits the scenario: normal PT and PTT but a bleeding tendency in rare patients. The other factors would typically alter PT or PTT (for example, VII affects PT, II affects both, and XII can affect aPTT in some labs but does not usually cause bleeding in vivo).

PT and aPTT measure the time it takes for initial clot formation, reflecting the enzymatic steps up to fibrin formation. Factor XIII is the final stabilizing step: it crosslinks and solidifies the fibrin clot after thrombin has formed fibrin. Because these tests assess how quickly a clot forms, not how well the formed clot is stabilized, a deficiency in Factor XIII does not lengthen PT or aPTT. Yet without crosslinking, the clot is unstable and can lead to clinically significant bleeding, even though routine screening tests are normal. This is why Factor XIII deficiency fits the scenario: normal PT and PTT but a bleeding tendency in rare patients. The other factors would typically alter PT or PTT (for example, VII affects PT, II affects both, and XII can affect aPTT in some labs but does not usually cause bleeding in vivo).